Here we evaluated the impact of TNF-α blockade by Infliximab on the ability of PBMCs derived from active and clinically cured tuberculosis patients and PPD+ healthy donors to form a granulomatous reaction through an in vitro model using mycobacterial antigens-coated polyacrylamide beads. This evidence concerns the gene TNF and tuberculosis.